These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1259 related articles for article (PubMed ID: 14551893)

  • 21. Experimental infection of Culex annulirostris, Culex gelidus, and Aedes vigilax with a yellow fever/Japanese encephalitis virus vaccine chimera (ChimeriVax-JE).
    Reid M; Mackenzie D; Baron A; Lehmann N; Lowry K; Aaskov J; Guirakhoo F; Monath TP
    Am J Trop Med Hyg; 2006 Oct; 75(4):659-63. PubMed ID: 17038690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A 5-year follow-up of antibody response in children vaccinated with single dose of live attenuated SA14-14-2 Japanese encephalitis vaccine: immunogenicity and anamnestic responses.
    Sohn YM; Tandan JB; Yoksan S; Ji M; Ohrr H
    Vaccine; 2008 Mar; 26(13):1638-43. PubMed ID: 18294743
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The suitability of yellow fever and Japanese encephalitis vaccines for immunization against West Nile virus.
    Yamshchikov G; Borisevich V; Kwok CW; Nistler R; Kohlmeier J; Seregin A; Chaporgina E; Benedict S; Yamshchikov V
    Vaccine; 2005 Sep; 23(39):4785-92. PubMed ID: 15939510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity.
    Monath TP; Lee CK; Julander JG; Brown A; Beasley DW; Watts DM; Hayman E; Guertin P; Makowiecki J; Crowell J; Levesque P; Bowick GC; Morin M; Fowler E; Trent DW
    Vaccine; 2010 May; 28(22):3827-40. PubMed ID: 20347059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy of mouse-brain inactivated Nakayama strain Japanese encephalitis vaccine--results from 30 years experience in Taiwan.
    Yang SE; Pan MJ; Tseng HF; Liau MY
    Vaccine; 2006 Mar; 24(14):2669-73. PubMed ID: 16314007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity of an inactivated Japanese encephalitis vaccine (JE-VAX) in humans over 20 years at USAMRIID: using PRNT50 as an endpoint for immunogenicity.
    Reisler RB; Danner DK; Gibbs PH
    Vaccine; 2010 Mar; 28(12):2436-41. PubMed ID: 20060946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Japanese encephalitis: new options for active immunization.
    Halstead SB; Thomas SJ
    Clin Infect Dis; 2010 Apr; 50(8):1155-64. PubMed ID: 20218889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Study on the strategy of Japanese encephalitis immunization using live attenuated vaccine combined with inactivated vaccine].
    Ma FB; Zheng L; Bi C; Tao H; Zhou YL; Zhang JL; Tang FY; Xie P; Zheng CZ; Peng WB; Jiang RJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Feb; 24(2):113-5. PubMed ID: 12697111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants.
    Gatchalian S; Yao Y; Zhou B; Zhang L; Yoksan S; Kelly K; Neuzil KM; Yaïch M; Jacobson J
    Vaccine; 2008 Apr; 26(18):2234-41. PubMed ID: 18394765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and Safety of a Booster Dose of a Live Attenuated Japanese Encephalitis Chimeric Vaccine Given 1 Year After Primary Immunization in Healthy Children in the Republic of Korea.
    Kim DS; Jang GC; Cha SH; Choi SH; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Bang J; Naimi Z; Bouckenooghe A; Bosch-Castells V; Houillon G
    Pediatr Infect Dis J; 2016 Feb; 35(2):e60-4. PubMed ID: 26535878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study.
    Schuller E; Jilma B; Voicu V; Golor G; Kollaritsch H; Kaltenböck A; Klade C; Tauber E
    Vaccine; 2008 Aug; 26(34):4382-6. PubMed ID: 18599165
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children.
    Chokephaibulkit K; Sirivichayakul C; Thisyakorn U; Pancharoen C; Boaz M; Bouckenooghe A; Feroldi E
    Vaccine; 2016 Nov; 34(46):5664-5669. PubMed ID: 27686833
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A large-scale study on the safety and epidemiological efficacy of Japanese encephalitis (JE) live vaccine (SA14-14-2) in the JE endemic areas].
    Zhou B; Jia L; Xu X
    Zhonghua Liu Xing Bing Xue Za Zhi; 1999 Feb; 20(1):38-41. PubMed ID: 10682513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine.
    Yun KW; Lee HJ; Park JY; Cho HK; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
    Vaccine; 2018 Mar; 36(11):1398-1404. PubMed ID: 29429815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protection of SA14-14-2 live attenuated Japanese encephalitis vaccine against the wild-type JE viruses.
    Jia L; Wang Z; Yu Y
    Chin Med J (Engl); 2003 Jun; 116(6):941-3. PubMed ID: 12877812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single dose of inactivated Japanese encephalitis vaccine with poly(gamma-glutamic acid) nanoparticles provides effective protection from Japanese encephalitis virus.
    Okamoto S; Yoshii H; Ishikawa T; Akagi T; Akashi M; Takahashi M; Yamanishi K; Mori Y
    Vaccine; 2008 Jan; 26(5):589-94. PubMed ID: 18180081
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) in children.
    Chokephaibulkit K; Houillon G; Feroldi E; Bouckenooghe A
    Expert Rev Vaccines; 2016; 15(2):153-66. PubMed ID: 26588242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Japanese encephalitis vaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy.
    Puthanakit T; Aurpibul L; Yoksan S; Sirisanthana T; Sirisanthana V
    Vaccine; 2007 Nov; 25(49):8257-61. PubMed ID: 17964009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity of one dose of Vero cell culture-derived Japanese encephalitis (JE) vaccine in adults previously vaccinated with mouse brain-derived JE vaccine.
    Woolpert T; Staples JE; Faix DJ; Nett RJ; Kosoy OI; Biggerstaff BJ; Johnson BW; Sracic M; Fischer M
    Vaccine; 2012 Apr; 30(20):3090-6. PubMed ID: 22406277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine.
    Tauber E; Kollaritsch H; von Sonnenburg F; Lademann M; Jilma B; Firbas C; Jelinek T; Beckett C; Knobloch J; McBride WJ; Schuller E; Kaltenböck A; Sun W; Lyons A
    J Infect Dis; 2008 Aug; 198(4):493-9. PubMed ID: 18588481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 63.